Abnormal Expression of WSB1 in Lung Adenocarcinoma: A Potential Prognostic and Immunotherapeutic Sensitivity Biomarker
Jiarui Xue , Tianying He , Shuqing Wang , Yan Liu
Advances in World Medical Research ›› 2025, Vol. 1 ›› Issue (2) : 48 -63.
This study aimed to conduct a pan-cancer analysis of WD40 Repeat-Containing SOCS Box Protein 1 (WSB1) through bioinformatics, detect its expression in lung adenocarcinoma (LUAD) tissues and adjacent normal tissues by immunohistochemistry (IHC), analyze its correlation with clinical indicators, and explore its diagnostic and prognostic value. We performed WSB1 bioinformatics analysis using data from multiple public databases (including TCGA, GTEx, HPA, CPTAC, etc.). IHC was used to detect the expression difference of WSB1 in LUAD tissues and adjacent normal tissues, followed by statistical processing and clinicopathological data analysis. Kaplan-Meier plotter was used to analyze the relationship between WSB1 expression and survival, and GO and KEGG pathway enrichment analyses were conducted to explore its functions. WSB1 was differentially expressed between various cancers and normal tissues. Specifically, WSB1 mRNA levels were downregulated in LUAD, while protein levels were significantly upregulated (P < 0.05). WSB1 expression was negatively correlated with LUAD distant metastasis (P < 0.05) and promoter methylation, and positively correlated with overall survival (OS), tumor immunity, and PDCD1. The genetic variation frequency of WSB1 was >4% (3.18% in LUAD), and there was no correlation with gender, age, etc. IHC validation (80 LUAD samples and 80 adjacent normal tissues) confirmed that WSB1 expression in LUAD tissues was significantly higher than that in adjacent normal tissues. WSB1 is upregulated at the protein level in LUAD and serves as a potential prognostic marker. It correlates with tumor immunity/PDCD1 (as a marker of immunotherapy sensitivity) and promoter methylation (through epigenetic regulation), and its abnormal expression may be caused by high-frequency mutations.
Lung Adenocarcinoma / WSB1 / Pan-Cancer Analysis / Immunohistochemistry
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
Chinese Society of Oncology, Chinese Medical Association. (2024). Clinical practice guidelines for lung cancer (2024 edition). Chinese Medical Journal, 104(34), 3175-3213. |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
/
| 〈 |
|
〉 |